Nucleai and Altis Labs are transforming clinical trials through AI innovation

The article explores the intersection of artificial intelligence (AI) and clinical trials in the biopharma industry. It highlights startups like Nucleai and Altis Labs that are leveraging AI to improve patient selection for clinical trials and predict clinical outcomes.

Nucleai‘s technology maps cancer cells and healthy cells to identify patterns for patient response to treatments, while Altis Labs focuses on predicting clinical outcomes by training algorithms on various patient data, including CT scans.

However, challenges such as regulatory approval, biases in data, and the need for diverse clinical trial participants remain significant hurdles. Despite these challenges, there is optimism about the potential of AI to revolutionize clinical trials and improve drug development processes.

Discover more here